ABSTRACT
This study aimed to develop a guideline for therapeutic drug monitoring (TDM) of vancomycin. We adopted the new guideline definition from the Institute of Medicine (IOM), adhered closely to the six domains of the Appraisal of Guidelines for Research & Evaluation II (AGREE II), and made recommendations based on systematic reviews. We established a Guideline Steering Group and a Guideline Development Group, formulated 12 questions in the form of Population, Intervention, Comparison, Outcome (PICO) and completed a literature search. As far as we know, we will develop the first evidenced-based guideline for vancomycin TDM under the framework of the Grade of Recommendations Assessment, Development and Evaluation (GRADE).
Subject(s)
Humans , Anti-Bacterial Agents , Economics , Pharmacokinetics , China , Drug Administration Schedule , Drug Monitoring , Methods , Evidence-Based Medicine , Methicillin-Resistant Staphylococcus aureus , Virulence , Staphylococcal Infections , Drug Therapy , Microbiology , Pathology , Vancomycin , Economics , PharmacokineticsABSTRACT
Actualmente existe gran inconsistencia en cómo los desarrolladores de guías clínicas en todo el mundo clasifican la calidad de la evidencia disponible y la fuerza de las recomendaciones, debido a que hay varios sistemas de clasificación. Por esa razón, los usuarios de las guías clínicas se enfrentan a retos profundos en la comprensión de guías clínicas. Importantes investigadores y gran número de ellos están adoptando el sistema GRADE para clasificar la calidad de la evidencia disponible y la fuerza de las recomendaciones cuando preparan manuscritos sobre guías clínicas. El sistema GRADE fue desarrollado por un grupo representativo de expertos en la elaboración de guías clínicas, muestra una clara separación entre el grado de evidencia y la fuerza de las recomendaciones, presenta una evaluación explícita sobre la importancia de los desenlaces finales de las diferentes estrategias de manejo, entre otras características. En esta breve revisión describimos las razones que explican la adopción de esta clasificación.
There is great inconsistency on how "Clinical Guideline Developers" worldwide rate the quality of evidence and strength of recommendations because there are several classification systems in use. Therefore, medical guideline users face profound challenges in understanding articles on Clinical Guidelines. Many researchers are adopting the GRADE system to classify the quality of the available evidence and the strength of recommendations when preparing a manuscript on Clinical Guidelines. The GRADE system has advantages over previous rating systems including being developed by a representative group of guideline developers, patent separation between quality of evidence and strength of recommendations, explicit evaluation of the importance of outcomes of alternative management strategies, and others. Consequently, in this brief review, we describe the reasons underlying the adoption of GRADE.